Rocket Pharmaceuticals, Inc. (RCKT) saw its stock soar by 5.20% during Thursday's intraday trading session, following the announcement of preliminary data from its Phase 1 clinical trial of RP-A601. The gene therapy candidate is being developed for the treatment of plakophilin-2 (PKP2) related arrhythmogenic cardiomyopathy, a rare and life-threatening heart condition.

The company presented the preliminary data at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, showcasing the potential of RP-A601 in addressing PKP2 arrhythmogenic cardiomyopathy. While specific details of the results were not provided in the available news, the positive market reaction suggests that the data may be promising for the treatment's future development and potential efficacy.

This development marks a significant milestone for Rocket Pharmaceuticals in its gene therapy pipeline. The strong market response indicates that investors are optimistic about the potential of RP-A601 and its impact on the company's future growth prospects. As Rocket Pharmaceuticals continues to advance its clinical programs, further positive results could potentially lead to additional stock price appreciation and increased interest from both the medical community and investors.